Loading
KCND2 (A-type voltage-gated potassium channel KCND2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons. This current is activated at membrane potentials that are below the threshold for action potentials.
Open Targets scores its association with cancer at 0.52 (direct and indirect evidence; datatypes literature 0.74, genetic association 0.28, clinical 0.76).
In plain words · KCND2 (A-type voltage-gated potassium channel KCND2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
KCND2 (A-type voltage-gated potassium channel KCND2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons.
No product in this corpus aims at KCND2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCND2: RNA tissue enriched (brain 32 nTPM); high antibody staining in 1 normal tissue. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KCND2 tissue; Open Targets ENSG00000184408 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Kong et al, Am. J. Physiol, 1998, "Isolation and characterization of the human gene encoding Ito: further diversity by alternative mRNA splicing". Source.
Sources: HGNC HGNC:6238 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NZV8 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000184408 (association with cancer (MONDO_0004992) 0.52; (GraphQL API, CC0))
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons. This current is activated at membrane potentials that are below the threshold for action potentials. It regulates neuronal excitability, prolongs the latency before the first spike in a series of action potentials, regulates the frequency of repetitive action potential firing, shortens the duration of action potentials and regulates the back-propagation of action potentials from the neuronal cell body to the dendrites. Contributes to the regulation of the circadian rhythm of action potential firing in suprachiasmatic nucleus neurons, which regulates the circadian rhythm of locomotor activity. Functions downstream of the metabotropic glutamate receptor GRM5 and plays a role in neuronal excitability and in nociception mediated by activation of GRM5. Location: Cell membrane; Cell projection, dendrite; Synapse; Perikaryon (UniProt). Locus 7q31.31 (HGNC).
RNA: tissue enriched (brain 32 nTPM), detected in some normal tissues.
Medium: Caudate.
RNA cancer enhanced: Glioblastoma Multiforme 13 pTPM.
No cancer sample stained medium or high.
HPA KCND2 tissue · HPA KCND2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KCND2" OR ABSTRACT:"KCND2" OR TITLE:"potassium voltage-gated channel subfamily D member 2" OR ABSTRACT:"potassium voltage-gated channel subfamily D member 2" OR TITLE:"A-type voltage-gated potassium channel KCND2" OR ABSTRACT:"A-type voltage-gated potassium channel KCND2" OR TITLE:"Kv4.2" OR ABSTRACT:"Kv4.2" OR TITLE:"RK5" OR ABSTRACT:"RK5" OR TITLE:"KIAA1044" OR ABSTRACT:"KIAA1044") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCND2, not a curated reading list.